Install
Send din pressemeddelelse med det samme Via Ritzau – den direkte linje til medierne.
- 270articles · 30d
- 12+ hour agolatest article
- Aug 18, 2026earliest in window
- 99%with images
- 248avg words
- Economy, Business & Finance 228
- Finance & Business 167
- News 115
- Business & Industrial 78
- Industrial 25
- Science & Technology 21
- Health & Wellness 20
- Medical 18
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Greywolf Therapeutics | Globenewswire
6+ day, 9+ hour ago (417+ words) Greywolf Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial OXFORD, United Kingdom, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Greywolf Therapeutics, the clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, today reports significant progress in their Phase…...
Xyra, LLC | Globenewswire
2+ week, 7+ hour ago (183+ words) XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation LOS ALTOS, California, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Open-label, dose-escalation study using cardiac rhythm data from implantable and wearable AF monitors allows…...
Lakefront Biotherapeutics | Globenewswire
2+ week, 6+ day ago (89+ words) U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus Gamgertamig is being developed by Lakefront in collaboration with Gilead Sciences. Ongoing clinical trials in autoimmune diseases are actively enrolling, and expansion of the clinical trials program is…...